msladyinca wrote:But none of them even come close to Tysabri's data, care to share the link for your Teva/Copaxone data so all of us can compare it to Tysabri's?
The study cohort consisted of 96 women and 12 men
It is especially critical for Biogen/Elan because recent comments in the financial world have stated that Tysabri sales aren't going to be anywhere near the original expectation of income.
So that's 108 Copaxone trial patients in the Czech Republic as opposed to 3,000 Tysabri US patients...with no data showing Improvement in QoL, no data for Significant Reduction in Steroid Use and Hospitalizations, and no data showing Cognitive Function Improvement...hardly seems worth the time to even mention Copaxone, but hey, that's just me.
Financial ANALysists aren't going to drive Tysabri uptake and demand, patients will.
Thanks for the first link, the second link revealed nothing as it didn't work, but thanks anyway Harry.
robbie wrote:i've been reading all the Ty forums and excuse my french but wtf. yes no, good bad, forsure maybe, how do you make a decision with this shit....
Users browsing this forum: No registered users